CONVINCE in the context of existing evidence on haemodiafiltration. Issue 6 (31st January 2022)

• Record Type: Journal Article
• Authors: Vernooij, Robin W M; Bots, Michiel L; Strippoli, Giovanni F M; Canaud, Bernard; Cromm, Krister; Woodward, Mark; Blankestijn, Peter J
• Is Part Of: Nephrology dialysis transplantation. Volume 37:Issue 6(2022)
• Page Start: 1006
• Page End: 1013
• Publication Date: 2022-01-31
• Subjects: Nephrology -- Periodicals; Hemodialysis -- Periodicals; Kidneys -- Transplantation -- Periodicals; Hemodialysis; Kidneys -- Transplantation; Nephrology; Periodicals; 616.61
• DOI: 10.1093/ndt/gfac019
• Languages: English
• ISSNs: 0931-0509

Abstract

ABSTRACT: Haemodiafiltration (HDF) provides a greater removal of larger solutes and protein-bound compounds than conventional high-flux haemodialysis (HD). There are indications that the patients receiving the highest convection volumes of HDF result in improved survival compared with HD. However, the comparative efficacy of HDF versus HD remains unproven. Here we provide a comparative account of the methodology and aims of 'the comparison of high-dose HDF with high-flux HD' (CONVINCE) study in the context of the totality of evidence and how this study will contribute to reaching a higher level of certainty regarding the comparative efficacy of HDF versus HD in people with end-stage kidney disease.